YAVNE, Israel, Sept. 11, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (“MediWound”), a fully integrated biopharmaceutical company focused on next-generation enzymatic...
FDA Acceptance of Libervant™ (diazepam) Buccal Film NDA for treatment of seizure clusters in patients between two and five years...
CAMBRIDGE, MA / ACCESSWIRE / September 8, 2023 / Moderna, Inc. (Nasdaq:MRNA) has been notified that TRC Capital Investment Corporation...
BOSTON, Sept. 08, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the...
Highlights AHI enters collaboration with His Excellency Dr Obaid Alketbi.Bin Farhood Group Founders have worked with and within the Government...
GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking medical device company that created the Swoop® system, the world’s first FDA-cleared...
TORONTO, ON / ACCESSWIRE / September 7, 2023 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), is a clinical...
Over 90 Percent of Connecticut Patients Used Telehealth to See Healthcare Providers Whom They Also Saw in Person NEW YORK,...
Investigational New Drug (IND) application submitted to U.S. Food and Drug Administration (FDA) for ELX-02 for the treatment of Alport...
Table 1 Table 1 Chart 1 Chart 1 Chart 2 Chart 2 Table 2 Table 2All study objectives were met,...
ESCRS presentations will feature clinical data on APX3330 in diabetic retinopathy; Nyxol® data in presbyopia, dim light vision disturbance and...
Carlsbad, CA, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a biopharmaceutical company advancing therapies for acute and chronic...
Results for adults and children ages 6 years and older from INTEGUMENT-OLE long-term extension trial highlight that 46.1% and 51.0%...
Arlington, Virginia, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Are you interested in promoting international cooperation in clinical engineering and healthcare...
CAMBRIDGE, MA / ACCESSWIRE / September 6, 2023 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in a fireside chat...
According to the analysis, MS and epilepsy patients experienced reduced annual healthcare costs of $6,280 and $4,600, respectively, on average...
Experienced Biopharma/Pharmaceutical Executive to Lead Implementation of cGMP-quality LineaDNA™ Capability for IVT mRNA ProductionPreviously Led Manufacturing Operations Scale-up for the...
TORONTO, ON / ACCESSWIRE / September 6, 2023 / Predictmedix AI Inc. (CSE:PMED)(OTCQB:PMEDF)(FRA:3QP) (the "Company" or "Predictmedix") today provided an...
CDC notes that the BA.2.86 (Pirola) variant may be more likely to break through existing immunity from previous vaccination or...
– Lead program, GT-2108 for the treatment of moderate-to-severe ulcerative colitis advancing toward completion of I ND-enabling studies with IND...